A clinical pharmacology study of CH5424802 in patients with ALK-positive NSCLC.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 09 Sep 2015 Interim results presented at the 16th World Conference on Lung Cancer.
- 02 Sep 2015 New trial record